BIO International Convention
The BIO International Convention 2026 brings together the global biotechnology community to address the practical challenge of turning biological innovation into scalable, reproducible, and decision‑ready outcomes. As biopharma workflows become more complex and data‑intensive, the industry focus has shifted from isolated experimentation toward operational execution—reducing variability, increasing throughput, and building confidence in data used to advance programs.
Visit Molecular Devices at Booth 5614 to see how integrated solutions, including AI‑enabled technologies, address common bottlenecks across discovery and cell line development workflows, including automation gaps, inconsistent data quality, slow insight generation, and limited scalability. Our solutions are built to help teams move from raw biological complexity to reliable, quantitative outcomes without adding operational burden.
At the booth, you’ll see how to:
- Accelerate and standardize cell line development by reducing manual colony selection and improving consistency with automated picking workflows.
- Measure functional assay readouts with confidence across absorbance, fluorescence, and luminescence applications, using flexible plate‑based detection as part of an integrated workflow.
- Support data integrity and reproducibility through controlled analysis and reporting workflows, including GxP‑aligned software environments that help maintain traceability from data acquisition to decision‑making.
- Generate consistent, high‑quality cellular imaging data that supports both exploratory research and scalable screening.
- Convert complex cellular images into reproducible biological insight using AI‑driven analysis that minimizes subjectivity and manual data handling.
- Scale high‑content screening workflows without increasing analysis complexity or dependence on specialized data science expertise.
Click below to schedule some time with our experts at Booth 5614 and explore practical, workflow‑level solutions for making biopharma research more robust, repeatable, and scalable.